Log in

NYSEARCA:BBCVirtus LifeSci Biotech Clinical Trials ETF Stock Price, Forecast & News

$41.92
+0.59 (+1.43 %)
(As of 08/10/2020 04:00 PM ET)
Add
Today's Range
$41.09
Now: $41.92
$42.20
50-Day Range
$38.83
MA: $42.20
$44.92
52-Week Range
$22.92
Now: $41.92
$45.70
Volume20,323 shs
Average Volume35,139 shs
Market Capitalization$48.21 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A

Geographic Exposure of BBC

Currency Exposure of BBC

Sector Exposure of BBC

Industry Exposure of BBC


Basic Details

Issuer Virtus
Fund NameVirtus LifeSci Biotech Clinical Trials ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:BBC
Inception Date12/16/2014
Fund ManagerMatthew B. Brown, Seth Kadushin
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkLifeSci Biotechnology Clinical Trials Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$47.54 million
Average Daily Volume$28,614.70
Discount/Premium-0.01%

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorVirtus ETF Solutions LLC
AdvisorVirtus ETF Advisers LLC
CustodianThe Bank of New York Mellon Corporation
DistributorETF Distributors LLC
Transfer AgentThe Bank of New York Mellon Corporation
Trustee
Lead Market MakerVirtu Financial
$41.92
+0.59 (+1.43 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BBC News and Ratings via Email

Sign-up to receive the latest news and ratings for BBC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Frequently Asked Questions

How has Virtus LifeSci Biotech Clinical Trials ETF's stock been impacted by COVID-19 (Coronavirus)?

Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $30.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BBC stock has increased by 39.2% and is now trading at $41.92.
View which stocks have been most impacted by Coronavirus
.

Has Virtus LifeSci Biotech Clinical Trials ETF been receiving favorable news coverage?

News coverage about BBC stock has been trending somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Virtus LifeSci Biotech Clinical Trials ETF earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Virtus LifeSci Biotech Clinical Trials ETF
.

What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Virtus LifeSci Biotech Clinical Trials ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Sanofi (SNY), Simon Property Group (SPG), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), Alibaba Group (BABA), Clovis Oncology (CLVS), Intel (INTC) and Micron Technology (MU).

What is Virtus LifeSci Biotech Clinical Trials ETF's stock symbol?

Virtus LifeSci Biotech Clinical Trials ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "BBC."

Who are Virtus LifeSci Biotech Clinical Trials ETF's major shareholders?

Virtus LifeSci Biotech Clinical Trials ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Niemann Capital Management Inc. (4.15%).
View institutional ownership trends for Virtus LifeSci Biotech Clinical Trials ETF
.

Which institutional investors are buying Virtus LifeSci Biotech Clinical Trials ETF stock?

BBC stock was bought by a variety of institutional investors in the last quarter, including Niemann Capital Management Inc..
View insider buying and selling activity for Virtus LifeSci Biotech Clinical Trials ETF
.

How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF?

Shares of BBC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Virtus LifeSci Biotech Clinical Trials ETF's stock price today?

One share of BBC stock can currently be purchased for approximately $41.92.

How big of a company is Virtus LifeSci Biotech Clinical Trials ETF?

Virtus LifeSci Biotech Clinical Trials ETF has a market capitalization of $48.21 million.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.